DoW Alzheimer’s Transforming Diagnosis Award

About this funding opportunity

Summary: The fiscal year 2026 (FY26) Alzheimer’s Research Program (AZRP) Transforming Diagnosis Award (TrDA) supports non-incremental, solutions-oriented research that reduces or overcomes important barriers to obtaining a diagnosis, meaningful disease monitoring and accurate prognosis.

Distinctive Features:

Clinical research is allowed, however clinical trials and animal research are prohibited.

Preliminary data are required.

Community collaboration is required for studies prospectively enrolling human subjects.

Study Population: The AZRP encourages studies to leverage existing cohorts/datasets. Cohorts consisting of individuals 65 years or younger are also encouraged.

Career Initiation or Transition (CIT) Partnership Option: The TrDA includes an option for more than one PI and supports both new and existing collaborative partnerships. If recommended for funding, each PI will be named on separate awards to the recipient organization(s). If utilizing this option, at least one independent investigator must meet the CIT Partnership Option eligibility requirements at the time of application submission.

Topic areas: General and Cross-cutting R&D, Life Sciences and Health.

Funding amount

This grant provides Varies in funding.

Deadline

Applications are due Sep 24, 2026. Confirm the exact closing time on the official program page before applying.

Who can apply

This opportunity is open to the following applicant types:

• Open to all applicant types

Eligibility

The program did not publish a separate eligibility statement. See the official opportunity page for the full eligibility criteria.

Agency

DoW Alzheimer’s Transforming Diagnosis Award is administered by Defense Health Agency Contracting Activity - DHACA (AMRAA), listed via Grants.gov.